Initiated three clinical trials in 2017 and on track to deliver three additional development programs in 2018 Neurology pipeline growing; candidate in spinocerebellar ataxia type 3 to be named by year end 2018 CAMBRIDGE, Mass. , March 12, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.